TY - JOUR
T1 - Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk
T2 - The European Prospective Investigation into Cancer and Nutrition (EPIC)
AU - Peeters, Petra H.M.
AU - Lukanova, Annekatrin
AU - Allen, Naomi
AU - Berrino, Franco
AU - Key, Tim
AU - Dossus, Laure
AU - Rinaldi, Sabina
AU - Van Gils, Carla H.
AU - Bueno-de-Mesquita, H. Bas
AU - Boeing, Heiner
AU - Schulz, Mandy
AU - Chang-Claude, Jenny
AU - Linseisen, Jakob
AU - Panico, Salvatore
AU - Sacerdote, Carlotta
AU - Palli, Domenico
AU - Tumino, Rosario
AU - Trichopoulou, Antonia
AU - Trichopolos, Dimitrios
AU - Bamia, Christina
AU - Larranaga, Nerea
AU - Ardanaz, Eva
AU - Pera, Guillem
AU - Quirós, J. Ramón
AU - Martínez-García, Carmen
AU - Navarro, Carmen
AU - Bingham, Sheila A.
AU - Khaw, Kay Tee
AU - Clavel, Françoise
AU - Tjonneland, Anne
AU - Olsen, Anja
AU - Overvad, Kim
AU - Tetsche, Mette S.
AU - Lund, Eiliv
AU - Lundin, Eva
AU - Berglund, Göran
AU - Riboli, Elio
AU - Kaaks, R.
PY - 2007/3
Y1 - 2007/3
N2 - We set out to study the relationship between circulating levels of IGF-I and its major binding protein (IGFBP-3) in relation to ovarian cancer risk. We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Levels of IGF-I and IGFBP-3 were measured in prediagnostic serum samples of 214 women who subsequently developed ovarian cancer, and 388 matched control subjects. Conditional logistic regression models were used to estimate relative risks of ovarian cancer by tertiles of IGF-I and IGFBP-3 levels. For all women, there was no association between the circulating IGF-I or IGFBP-3 levels and the risk of ovarian cancer. However, among women diagnosed with ovarian cancer aged 55 or younger, the relative risk was higher in the middle or top tertiles of serum IGF-I, when compared with women in the lowest tertile (odds ratios (OR)=1.8 (95%CI 0.7-4.3) and OR=2.4 (95%CI 0.9-6.4); Ptrend=0.08) respectively. These results were adjusted for body mass index, previous hormone use, fertility problems, and parity. Restricting the analysis to women who were premenopausal at blood donation, relative risks for ovarian cancer diagnosed before age 55 were higher (OR=5.1 (95%CI 1.5-18.2) and OR=5.6 (95%CI 1.5-20.8) respectively, for second and third tertiles; Ptrend=0.02). Adjustment for serum IGFBP-3 levels only slightly attenuated relative risk estimates. Relations between IGFBP-3 and ovarian cancer before age 55 were in the same direction as for IGF-I, but less strong and statistically not significant. In women aged over 55, there was no association between serum IGF-I or IGFBP-3 and ovarian cancer risk. Our results suggest that the circulating levels of IGF-I may play a potentially important role in the development of ovarian cancer in women of a pre- or perimenopausal age.
AB - We set out to study the relationship between circulating levels of IGF-I and its major binding protein (IGFBP-3) in relation to ovarian cancer risk. We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Levels of IGF-I and IGFBP-3 were measured in prediagnostic serum samples of 214 women who subsequently developed ovarian cancer, and 388 matched control subjects. Conditional logistic regression models were used to estimate relative risks of ovarian cancer by tertiles of IGF-I and IGFBP-3 levels. For all women, there was no association between the circulating IGF-I or IGFBP-3 levels and the risk of ovarian cancer. However, among women diagnosed with ovarian cancer aged 55 or younger, the relative risk was higher in the middle or top tertiles of serum IGF-I, when compared with women in the lowest tertile (odds ratios (OR)=1.8 (95%CI 0.7-4.3) and OR=2.4 (95%CI 0.9-6.4); Ptrend=0.08) respectively. These results were adjusted for body mass index, previous hormone use, fertility problems, and parity. Restricting the analysis to women who were premenopausal at blood donation, relative risks for ovarian cancer diagnosed before age 55 were higher (OR=5.1 (95%CI 1.5-18.2) and OR=5.6 (95%CI 1.5-20.8) respectively, for second and third tertiles; Ptrend=0.02). Adjustment for serum IGFBP-3 levels only slightly attenuated relative risk estimates. Relations between IGFBP-3 and ovarian cancer before age 55 were in the same direction as for IGF-I, but less strong and statistically not significant. In women aged over 55, there was no association between serum IGF-I or IGFBP-3 and ovarian cancer risk. Our results suggest that the circulating levels of IGF-I may play a potentially important role in the development of ovarian cancer in women of a pre- or perimenopausal age.
UR - https://www.scopus.com/pages/publications/34249777562
U2 - 10.1677/erc.1.01264
DO - 10.1677/erc.1.01264
M3 - Article
SN - 1351-0088
VL - 14
SP - 81
EP - 90
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
IS - 1
ER -
